Aleafia Health Inc (AH.DB)

ALEAF CUSIP suspended. FINRA deleted symbol.

https://otce.finra.org/otce/dailyList?viewType=Deletions

15000 shares traded today???? Really???? $ALEAF

So strange

ALEAF: reinstated to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

ALEAF: inactive security. FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

Should be worth more than a penny.

SCAM!!!!!

This is the latest information I have been able to find. As I read it. They have been granted an extention till Jan and have somehow been granted credit😂
https://www.ksvadvisory.com/docs/default-source/insolvency-case-documents/aleafia-health/ccaa-proceedings/court-orders/endorsement-of-justice-penny-dated-november-27-2023.pdf?sfvrsn=95f38b61_1

Time for a class action law suit!!! Lets do this??????

That being said, they are still working on the restructuring so it could go either way

Possibly, we will know soon one way or another :) I am happy to have invested in the world being a better place. Without us little retailers the industry would not exist. I do not consider it a loss.

DID WE JUST LOSE ALL OUR MONEY!!!!!!!!!!!! FOREVER!!!!!!!!!!!!!!

Would not surprise me.

The only recourse may be a class action lawsuit but there are many hoops to jump through to get one going.

Realistically, sadly-All got taken for a ride since legalization in Canada.

The insiders got rich while retail got screwed over.

Aleafia Health Inc.

85 Basaltic Rd
Concord, ON
L4K 1G4

Office: 416-860-5665
Fax: 416-860-5626

INVESTOR & MEDIA RELATIONS

IR@AleafiaHealth.com

All part of their plan and all part of the stock market game and related personal choices.

Was the insider who voted against the merger a person who benefits from this restructuring? If so, what is the recourse of the investors shut out with what seem to be now worthless holdings?

Aleafia Health Obtains Creditor Protection to Pursue Restructuring and Sale Process

https://financialpost.com/globe-newswire/aleafia-health-obtains-creditor-protection-to-pursue-restructuring-and-sale-process/wcm/f73f4a94-fd8b-4163-bcbc-4df2dbf1f938/amp/

Red White & Bloom and Aleafia Health Mutually Agree to Terminate Binding Letter Agreement

https://financialpost.com/globe-newswire/red-white-bloom-and-aleafia-health-mutually-agree-to-terminate-binding-letter-agreement/wcm/a00a4465-da97-449e-91bd-19750946539b/amp/

Aleafia Health Announces Fourth Quarter and Annual Financial Results

Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”) versus $10.7 million for the period ended March 31, 2022

Net revenue increased 33% to $9.4 million for Q4 FY2023 versus $7.0 million for the period ended March 31, 2022

Revenue increased 24% to $57.4 million for the 12 months ended March 31, 2023 (“FY2023”) over the twelve months ended March 31, 2022

Net revenue increased 19% to $42.8 million for FY2023 over the twelve months ended March 31, 2022

#5 and #2 market share ranking in Divvy pre-roll and milled product formats in Q4 FY2023 in Ontario1

318% growth in international net revenue2 in FY2023 over the twelve months ended March 31, 2022

Third consecutive quarter of positive Adjusted EBITDA3 achieved in Q4 FY2023

https://financialpost.com/globe-newswire/aleafia-health-announces-fourth-quarter-and-annual-financial-results

Lets hope we all have luck in the future. :)

Split down the road ?

That is true.

Beats bankruptcy though.

GL!

I did and will set it and forget it.

It’s a slot/lotto play at this time.

GLTU/A!

though red white and bloom are no great shakes...

saved from imminent death. exposure to the US. it could have been a lot worse.

Is this sale a good thing long term?

Worth buying more?

Red White & Bloom and Aleafia Health Execute Binding Letter Agreement for Business Combination

https://financialpost.com/globe-newswire/red-white-bloom-and-aleafia-health-execute-binding-letter-agreement-for-business-combination

Aleafia Health Announces Amendments to Credit Facility and Strategic Review Process

https://ca.finance.yahoo.com/news/aleafia-health-announces-amendments-credit-113000022.html

200 day above the 50 and 2x the average volume on an up day. Our patience may soon be rewarded. I never assume anything in this industry but it looks promising

I think it is because they are in an industry that just started as legal in 2017 where they just got actual stores open 2 years ago and they sell a product nobody is allowed to advertise. The only people who can invest in the industry are retail investors because corporations and banks and hedge funds are not permitted in the OTC or cannabis touching businesses might be a few reasons as a start. Impatient people prefer the activity of trading. I have been investing in the cannabis industry since Tweed went public. Made a bunch there and have redeployed my $ into this industry on a more diversified basis. The large LPs are a joke now. Constellation trashed Canopy. Glad I got out when the takeover happened. IMO the best bet in Canada is in Aleafia because they understand CPG is the future. I am watching a couple of other names but Aleafia is the only Cdn LP I own at the moment This is a nascent global industry that offers a product that is so beneficial people are willing to risk prison for. In my opinion this is the greatest opportunity to make generational wealth I will see in my lifetime. I hope that clarifies the situation. Not a normal industry. That is why it is such an extreme opportunity.

Sounds real good. So why are in the three cent range ?

They have been doing what they say they will. I have family that is a patient and what they say about the products is true.
https://www.benzinga.com/markets/cannabis/23/04/31652205/this-cannabis-company-just-signed-a-new-deal-in-europes-largest-and-most-profitable-medical-cann

Aleafia Health Announces Q3 FY2023 Results, International Expansion and Second Quarter of Profitability

https://www.globenewswire.com/news-release/2023/02/13/2606529/0/en/Aleafia-Health-Announces-Q3-FY2023-Results-International-Expansion-and-Second-Quarter-of-Profitability.html

I'm happy someone is enabling Aleafia to stay in business.

Aleafia Health to Announce Fiscal Year 2023 Third Quarter Results

https://www.globenewswire.com/news-release/2023/02/01/2599349/0/en/Aleafia-Health-to-Announce-Fiscal-Year-2023-Third-Quarter-Results.html

Thanks ... An inch at a time ... Aleafia Health Announces New International Partner, Strengthening Connections in High-Potential European Market
New Board Chair Also Named

TORONTO, January 30, 2023 – Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that it has signed a new European cannabis distribution partner, representing a one-year, approximately $1 million contract[1], significantly bolstering the Company’s record $1.2 million year-to-date sales in its growing international channel.

“This new announcement is very significant: it builds upon advancements made in August 2022 when the Company revealed a two-year $4.6 million European sales commitment and broadens our international reach,” said Aleafia CEO Tricia Symmes. “The Company is involved in overseas markets because international success leverages both its products and brands, and the addressable European cannabis market is high potential, so this relationship provides another gateway into further European expansion in the medical and potential recreational markets.”

“These international agreements are an important part of our strategic plan for growth and profitability,” said Matt Sale, CFO. “These activities grow revenue, are not subject to excise duties, lock in attractive margins, and improve our overall cash conversion cycle and net working capital performance, continuing to deliver against one of our core sale pillars for FY 2023.”

David Pasieka Replaces Mark Sandler as Aleafia Health Board Chair
The Company also announced that David Pasieka, a director since September 2021, will become its Board Chair, following the January 30th retirement of Mark Sandler, who has served as Chair since July 2021 and is Aleafia Health’s longest serving director having being appointed in 2018. Pasieka, a seasoned public company executive, with extensive formal and board level experience, has served on Aleafia’s FAC and HRC committees and currently serves on the Board of Oakville Hydro / Oakville Enterprise Corporation as well as serving on the Faculty of the Caribbean Governance Institute.

“The Company has been very grateful for Mark Sandler’s counsel and support of the vision for the future as we transitioned from a bulk wholesale cannabis provider into a branded adult-use, medical and international producer. Under his guidance, the Company consistently increased market share, achieved a top 10 standing in multiple formats and markets for Divvy, negotiated the amendment of its $37.3 Million Convertible Debentures while securing a $5.6 million equity financing in June 2022,” said Symmes. “Since becoming CEO in February 2022, I benefited from Mark’s thoughtful insights in our concerted drive toward Adjusted breakeven EBITDA profitability[2], which was achieved two quarters ahead of projections. Now David Pasieka will build on those accomplishments, guiding us to further growth and enhanced profitability.”

For Investor & Media Relations
Matthew Sale, CFO
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:
The Company is a federally licensed Canadian cannabis company offering cannabis products in Canadian adult-use and medical markets and in select international markets, including Australia and Germany. The Company operates a virtual medical cannabis clinic staffed by physicians and nurse practitioners which provide health and wellness services across Canada.
The Company owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the largest, outdoor cannabis cultivation facility in Canada. The Company produces a diverse portfolio of cannabis and cannabis derivative products including dried flower, pre-roll, milled, vapes, oils, capsules, edibles, sublingual strips, and topicals.

Cautionary Statement on Non-IFRS Measures
Adjusted EBITDA is not a recognized financial measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. For additional information including the definition and purpose of the non-IFRS measure, see “Cautionary Statement re Non-IFRS measures” in the Company’s Management’s Discussion and Analysis for the period ended September 30, 2022 found on SEDAR at www.sedar.com.

Forward Looking Information Cautionary Statement
Certain statements herein relating to the Company constitute “forward looking information”, within the meaning of applicable securities laws, including without limitation, statements regarding the value of contracts. Such forward-looking statements involve unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward looking statements include, but are not limited to, statements with respect to our long term profitability, market share, net revenue, branded cannabis net revenue, Adjusted EBITDA, projected value of contracts and other financial outlook projections for fiscal year 2023, our commercial operations, including production and / or sales of cannabis, quantities of future cannabis production, anticipated revenue in connection with such sales, and other Information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. The following material factors or assumptions were used to develop the forward looking information: Aleafia’s ability to cultivate, harvest and deliver sufficient flower compliant with regulatory and contractual specifications to meet demand, our new European partner will purchase the minimum quantity contractually required to maintain its exclusivity rights, information provided by our new European partner on their future purchasing plans is accurate, our new European customer will comply with its contractual commitments, Euro to Canadian collar currency conversion rates and costs remain stable, market size and growth of the Canadian adult-use and medical cannabis markets and international markets, retail store penetration, script trends, cultivation and processing capacity, costs of production, gross and net revenue per gram. Actual results may differ materially from those expressed or implied by such forward looking statements and involve risk and uncertainties relating to: currency conversion costs, value of foreign and Canadian currencies, future cultivation yield and quality, actual operating performance of facilities, product launches, facility licenses and amendments, average selling prices, cost of goods sold, operating expenses, Adjusted EBITDA, regulatory changes in the Canadian and international markets, and other uninsured risks. The forward looking information was approved by Management as of January 10, 2023. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. The forward looking information is provided for information purposes only and readers are cautioned that it may not be appropriate for other purposes. This presentation is provided for general information purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.

Aleafia Health Announces New International Partner, Strengthening Connections in High-Potential European Market

https://www.globenewswire.com/news-release/2023/01/30/2597453/0/en/Aleafia-Health-Announces-New-International-Partner-Strengthening-Connections-in-High-Potential-European-Market.html

Aleafia Health Successfully Completes TSX Review and Announces Entry into Fifth Province

https://www.globenewswire.com/news-release/2022/11/28/2563346/0/en/Aleafia-Health-Successfully-Completes-TSX-Review-and-Announces-Entry-into-Fifth-Province.html

If I was buying and flipping I could have made money. This is a sad one.

Aleafia Health Announces Achieving Major Profitability Milestone Ahead of Target and $10.6 Million Total Net Revenue in Q2 FY2023

https://financialpost.com/globe-newswire/aleafia-health-announces-achieving-major-profitability-milestone-ahead-of-target-and-10-6-million-total-net-revenue-in-q2-fy2023/wcm/8e5811f8-1712-44f0-8abc-44fe319efa7b/amp/

GLTA

Good luck.

Thank you.

GL!

Thanks FM.

I jumped back in nicely recently as the PPS was hard to resist.

My research into the sales in my local dispensary’s (and my personal experiences with their product lines) led me to do so.

GLTU/A

Aleafia Health to Announce Fiscal Year 2023 Second Quarter Results

TORONTO, November 2, 2022 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will announce on November 9 prior to market open its fiscal year 2023 second quarter results for the period ending September 30, 2022. The Company will also host its earnings conference call the same day at 8:30 a.m. EST. The call will be hosted by CEO Tricia Symmes and CFO Matt Sale.


CONFERENCE CALL & WEBCAST
Date: November 9, 2022
Time: 8:30 a.m. EST
Webcast Link
Phone Registration Link

This conference call will be webcast live over the internet and can be accessed through the link provided above. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. Participants who miss the live call can view a replay at any time via the link provided.
For Investor & Media Relations:

Matthew Sale, CFO

1-833-879-2533

IR@AleafiaHealth.com

LEARN MORE: www.AleafiaHealth.com

Aleafia Health Expands Sunday Market House of Brands With Coveted Lineup of Winter Product Launches

They keep moving and shaking. I just can't believe they've lost so much money and can remain in business. - FUNMAN

16 total new listings added to the Sunday Market portfolio by February 2023

9 new Divvy products in profitable flower, vape, and milled categories

Kin Slips portfolio expands to include the California brand’s best-selling CBN product Shut Eye Plus

CBD-forward brand Noon & Night extends giftable CBD product lineup

Innovative Bogart’s Kitchen portfolio adds to condiment offering with classic Canadian pantry staple

TORONTO, November 1, 2022 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the launch of the Sunday Market House of Brands winter product lineup for the adult-use market. This season, consumers from Ontario to British Columbia will have the opportunity to gift something for everyone on their adult list, and enjoy many new products, with the Company introducing 8 unique new SKUs hitting core markets before the Holidays, with a total of 16 new product listings by February 2023.

Divvy Buyer’s Club: The Company is introducing a new high-THC 7g flower offering with Divvy Buyer’s Club, sourced from trusted cultivation partners. The discerning Divvy procurement team will be choosing a rotating SKU of single strain, high-THC dried flower, an ever-changing exciting selection available this November exclusively at Ontario and Alberta brick and mortar licensed cannabis stores, with potential for other provinces by year end.

Also new in the flower category, Divvy introduces Incredible Milk, a new high-THC flower in both 3.5g and 14g sizes, as well as Cropped Harvest CBD, the Company’s milled flower 14g product. Both arrived in Alberta this month and will launch in licensed Ontario stores and online at ocs.ca in November.

Deepen Product Offering with Balanced CBD Strain: The Company expands its THC:CBD balanced Black Widow portfolio. Already a popular strain in Divvy’s iconic 12x0.35g pre-roll packs and 14g bags of flower, Black Widow launches in Alberta and Ontario this November in a convenient and discreet 1.0g vape cartridge for those wanting mostly CBD but with a little THC added.

Noon & Night Everyday Rollers: For the CBD-focused consumer, Aleafia’s wellness brand Noon & Night introduces a product pairing: two roll-ons with complementary sensations and applications. Infused with 200mg of CBD in a 9.8mL applicator, Everyday Rollers matches Freshly Minted with new Shinrin Yoku, a sweet citrus, awakening pine, and warming camphor “forest bath” for the senses.

Kin Slips Shut Eye Plus: A lineup extension from California’s Kin Slips brand, Shut Eye Plus, a new-to-Canada version of the popular sublingual strip, offers a balanced 5mg THC, 5mg CBD, and 5mg CBN cannabinoid profile in a 10-pack that is fast-acting, discreet, and entirely plant-based. Launching in November, it will first be available in Ontario and Alberta.

Bogart’s Kitchen Maple Syrup: Bogart’s Kitchen, the brand that created last year’s holiday edible must-have, brings something sweet and classically Canadian to holiday mornings this year: THC-infused Quebec Maple Syrup. With minimal cannabis aftertaste, and perfect for that warm stack of pancakes at breakfast, this new pantry staple contains 10mg THC in a 40ml bottle.

“Both the success of our Divvy brand and the innovation our other Sunday Market brands have demonstrated has given the provincial boards the belief in our portfolio to bring critical new listings in highly sought-after categories at this crucial time of the year for retailers. We are thrilled to bring more new and giftable products to our core markets this holiday season,” said Tricia Symmes, CEO. “To have the opportunity to make holiday gatherings brighter for consumers across the country, after the last two challenging holiday seasons, makes this an exciting time for a growing Canadian cannabis company fulfilling its core mission of supplying the highest quality, in-demand brands to loyal and dedicated consumers.”

“We are pleased to announce the addition of targeted new product listings which further deepen the product offering in our core brand, Divvy, while increasing the offering in our other brands. We are strategically adding SKUs where there is strong unmet consumer demand and we can also drive profitable growth in Aleafia, a critical element for long-term sustainability of the Company,” said Matt Sale, CFO.

Each of these new products will also be available to patients through Emblem, Aleafia’s medical brand.

For Investor & Media Relations:

Matthew Sale, CFO
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

I am holding and buying more. Imo it is the best play in Canada atm. They are gaining market share and offering new products while the “big” names are slipping. I was considering an exit in the summer but they renegotiated with their lenders who accepted a deal with a price higher than market at the time. It is not possible to apply the same metrics to an emerging market as to a mature one. I have averaged down and honestly think this has a shot at success. Their medical line is expanding and divy sells well according to my local dispensary. Not all my picks are going to make it but I do think this one has a shot.

Haven’t checked in for a while.

Sad to see how corporate mismanagement has decimated the PPS over the past year or two.

I hope there is a turnaround at some point before declaring bankruptcy is necessary.

I have used and used their products and have no complaints with them.

The blame rests on the BOD only.

Why isn't there a chart for half of the companies since the change of the ihub platform? It sucks now I am really disappointed with ihub now. I got great info and was able to get great insights from other users till that change. I will not be renewing my paid participation after this year. I will not pay to be disappointed lol!

Aleafia Health Announces Results of Annual General Meeting
TORONTO, September 29, 2022 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the results of the vote on the election of directors at its annual meeting of shareholders held on September 27, 2022 (the “Meeting”). All six nominees set out in the management information circular of the Company dated August 19, 2022 were elected to the board of directors (the “Board”) of the Company.


Nominee For Against Withheld Non Vote For Against Withheld
Mark Sandler 67,007,871 1,632,272 0 23,208,803 97.62% 2.38% 0.00%
Luciano Galasso 67,165,098 1,475,045 0 23,208,803 97.85% 2.15% 0.00%
Ian Troop 67,240,952 1,399,191 0 23,208,803 97.96% 2.04% 0.00%
David Pasieka 67,167,928 1,472,215 0 23,208,803 97.86% 2.14% 0.00%
Jon Pereira 67,185,790 1,454,353 0 23,208,803 97.88% 2.12% 0.00%
Carlo Sistilli 67,209,871 1,430,272 0 23,208,803 97.92% 2.08% 0.00%

Final voting results on all matters will be filed on the Company’s SEDAR profile at www.sedar.com.

For Investor & Media Relations:

Matthew Sale, CFO
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

Why are we still stuck at a shit price!!!!!

Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing a 13% Increase Over the Prior Year

https://mailchi.mp/aleafiahealth.com/aleafia-health-announces-120-million-total-net-revenue-in-first-quarter-representing-a-13-increase-over-the-prior-year?e=02506ded3e

• 31% increase in branded cannabis net revenue[1] to $10.0 million from $7.6 million in the prior year
• #12 ranking for market share in core markets[2] for Q1 FY2023
• In the Ontario value category, Divvy has attained #5 market share in pre-roll and #7 in flower
• Secured new international partnership representing approximately $4.6 million sales commitment
• 12% increase in medical cannabis net revenue[3] over the prior quarter
• 7.5% market share in overall Canadian medical market
• Reaffirmed guidance of $53.0 to $63.0 million in net revenue in FY2023[4]
• Trending towards breakeven Adjusted EBITDA[5] profitability with -$0.9 million in Q1 FY2023; reaffirmed guidance of achieving run-rate breakeven Adjusted EBITDA in FY2023[6]
• Nitecaps, a breakthrough melatonin-CBD product launch in current quarter

TORONTO, August 11, 2022 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to report its financial results for the three months ended June 30, 2022, its first quarter of its fiscal year ending March 31, 2023 (“FY2023”).

Branded cannabis net revenue, quarter over quarter, increased 25%: Aleafia Health continued its upward sales growth trend, with branded cannabis net revenue increasing 24% to a record $10.0 million from $8.0 million quarter over quarter. In the key branded adult-use market, the Company’s net revenue[7] increased 107% to $6.7 million from $3.2 million in the same period last year.

“Our pivot to a branded cannabis strategy is the success story driving the three pillars of company revenue: adult-use branded cannabis, a ‘sticky’ recurring medical cannabis revenue stream and growing higher margin international sales,” said Aleafia Health CEO Tricia Symmes. “As a result of revenue increases, the Company has achieved the 2nd highest growth rate amongst top 12 Canadian LPs in retail sell through over the prior quarter while achieving a #12 ranking for market share in our core markets for Q2 CY2022.”[8]

“Due to our successful branded growth strategy, the Company continues to target a top 10 standing[9] in our key markets and reaffirms our expectation to reach breakeven Adjusted EBITDA profitability during the second half of FY2023,”[10] said Aleafia Health CFO Matt Sale. “Showing continued success in retail sell through provides us the confidence to reaffirm our guidance to deliver at least $53 million in total net revenue in fiscal year 2023[11], with a current run-rate of $48 million.”

Divvy Brand Leadership: “In each of the three largest revenue categories - flower, pre-rolls and vapes - the Company is gaining in market share and continuing to deliver excellent growth rates,” Symmes said. “In the Ontario value category, Divvy flower enjoys a #7 market share ranking (with 3.4% share), pre-rolls enjoy a #5 ranking (with a 6.9% share), and our recently launched vape products continue to grab market share amidst a highly competitive format, and enjoy a 1.4% market share.”[12]

Medical: The Company reported a 4% increase in medical cannabis net revenue to $2.8 million in Q1 FY2023 over $2.5 million in the prior quarter. This represents a $11 million run-rate net revenue base. Moreover, the Company has attained a milestone 7.5% market share in the overall Canadian medical market, according to Health Canada data.[13] “In a competitive medical cannabis segment, market share has increased and we have restarted our growth trajectory over the last two quarters,” said Symmes. “We continue to penetrate the Quebec market with a 71% quarter over quarter increase in patient registrations. Growth in Quebec has helped to offset industry wide medical channel decline which has also affected our business. Sales to veterans also increased 4% quarter over quarter.”

“Anchored by our Emblem brand, we continue to view medical as a core part of our diversified sales mix, and is synergistic with our branded adult-use channel given the ability to sell products into both segments," said Sale.

International Revenue Growth: “International revenue is a competitive advantage and a differentiating factor for Aleafia, as we leverage our high quality, diversified flower supply and export it to the higher margin international sales markets,” Symmes said. “Current international agreements have led to more than $0.5 million in sales to Germany and Australia this quarter. We have also secured a new European partner with a $4.6 million sales commitment, representing further channel development. International success leverages both the Company’s products and its brands.”

“The newly signed agreement improves revenue and cash flow visibility, locks in attractive margins, and improves our overall cash conversion cycle and net working capital performance,” said Sale.

Continued Cost Rationalization: “We are striving to achieve breakeven Adjusted EBITDA profitability by the end of FY2023,” Sale said. “Firstly, we are increasing revenue by capturing market share. SKU optimization has furthered revenue growth, which aligns the portfolio with the highest selling product formats with strongest margins, coupled with moderate and strategic price increases. Second, we are relentlessly focused on cost rationalization. In addition to difficult headcount reductions and other initiatives, the Company has engaged in vendor consolidation to reduce complexity across sites while negotiating trusted vendor price improvements due to economies of scale. With all of these efforts combined, the Company has extracted $20 million in annualized SG&A savings over the last four quarters, and break-even Adjusted EBITDA profitability is within our grasp during FY2023, a milestone for the Company.”

“On the cultivation side of the business, all processes in our Grimsby, Ont. hybrid greenhouse have been remapped to allow it to meet anticipated growing throughput of high potency THC flower,” said Sale. “With strategic investments to improve flower consistency and quality, we continue to see steady improvements in Grimsby.”

New Nitecaps: “In Q1 FY2023, the Company completed development on a breakthrough product that has just been brought to the Ontario and Alberta markets this month,” said Symmes. “Our Noon & Night Nitecaps softgels with CBD suspended in melatonin and-MCT oil are an industry first.”

“We are highly strategic and thoughtful about our new product roll-outs. In this case, Nitecaps can be leveraged in the adult-use and medical channels as sleep is top-of-mind for many patients, addressing an unmet consumer need,” said Sale.

“Aleafia Health today is a vastly different Company than it was one year ago,” said Symmes. “With an extraordinary team of people at all levels, we are now positioned to reach new heights, supported by cost containment, a transforming balance sheet, and new equity financing. We are now rooted in a new era, with a relentless drive toward profitability and increased market share capture.”


For Investor & Media Relations:

Matthew Sale, CFO
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:
The Company is a federally licensed Canadian cannabis company offering cannabis products in Canadian adult-use and medical markets and in select international markets, including Australia and Germany. The Company operates a virtual medical cannabis clinic staffed by physicians and nurse practitioners which provide health and wellness services across Canada.
The Company owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the largest, outdoor cannabis cultivation facility in Canada. The Company produces a diverse portfolio of cannabis and cannabis derivative products including dried flower, pre-roll, milled, vapes, oils, capsules, edibles, sublingual strips, and topicals.

Forward Looking Information

Certain statements herein relating to the Company constitute “forward looking information”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward-looking information”. Such forward-looking statements involve unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward looking statements include, but are not limited to, statements with respect to our market share, net revenue, branded cannabis net revenue, Adjusted EBITDA, and other financial outlook projections for fiscal year 2023, our commercial operations, including production and / or sales of cannabis, quantities of future cannabis production, anticipated revenue in connection with such sales, and other Information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. The following material factors or assumptions were used to develop the forward looking information: market size and growth of the Canadian adult-use and medical cannabis markets, retail store penetration, script trends, cultivation and processing capacity, costs of production, gross and net revenue per gram. Actual results may differ materially from those expressed or implied by such forward looking statements and involve risk and uncertainties relating to: future cultivation yield and quality, actual operating performance of facilities, product launches, facility licenses and amendments, average selling prices, cost of goods sold, operating expenses, Adjusted EBITDA, regulatory changes in the Canadian and international markets, and other uninsured risks. The forward looking information was approved by Management as of August 10, 2022. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. The forward looking information is provided for information purposes only and readers are cautioned that it may not be appropriate for other purposes. This presentation is provided for general information purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.